43LOW

NEU

NEUREN FPO NZ [NEU]
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develops NNZ-2591, which is in Preclinical trial stage for the treatment of Prader-Willi syndrome. The company was incorporated in 2001 and is based in Hawthorn East, Australia.
Healthcare · ASX Small Cap
$11.9450 +0.1%

Updated 26 Mar 2026 · Scores refresh every scan

Score Breakdown

Technical69
Catalyst50
Sentiment50
Fundamental52
Momentum22
Risk Gate36
Get alerts when NEU's score changes
Free watchlist with daily scans for 2,200+ ASX stocks
Track NEU — Free

Active Signals

Bullish Signals

  • RSI drifting toward oversold territory — worth watching
  • MACD momentum is picking up steam
  • Volatility is contracting — like a spring being compressed, breakouts often follow
  • Cash positive / operating cashflow positive
  • Revenue in sharp decline (-81%)
  • Piotroski F-Score strong (7/9, low-confidence approx)
  • EPS estimates revised upward (+10pts)
  • Elevated short interest (5.9%)
  • Short interest rising (+1.5% in 5d)
  • Earnings in sharp decline (-88% QoQ)
  • CANSLIM A: Turned profitable
  • CANSLIM I: Institutional ownership (23%)
  • Healthy profit margins (47%)
  • Sentiment is mixed — no strong consensus either way
  • Altman Z-Score grey zone (2.35, low-confidence approx)
  • Days to cover very high (10.9)
  • RBA hiking (-3pts)

Risk Signals

  • Below the 200-day average — the long-term trend is still working against it
  • Post-earnings drift: negative surprise (SUE -10)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Earnings momentum has turned negative — worth checking what's behind it
  • Revenue declining at -81% — the top line is shrinking
  • The bigger volume days are the down days — volume-weighted momentum is negative (-1.14%/day)
  • Overseas neutral (-2pts, S&P500 neutral, VIX 25)
Ask Scout AI about NEU
"What's driving NEU's score?" "How does NEU compare to peers?" "Key risks for NEU?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE Update - Notification of buy-back - NEU
NONE Update - Notification of buy-back - NEU
NONE Update - Notification of buy-back - NEU

Recent ASX Announcements

2026-03-23 Update - Notification of buy-back - NEU
2026-03-12 Update - Notification of buy-back - NEU
2026-03-09 Update - Notification of buy-back - NEU
2026-03-05 Change of Director's Interest Notice - J Basile
2026-03-03 Update - Notification of buy-back - NEU

Key Metrics

$1.5B
Market Cap
683K
Avg Volume
1.8x
Vol Ratio
$8.61 — $22.98
52-Week Range
5.9%
Short Interest
N/A
Cash Runway
8.7%
ROE
47.1%
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: -88%
AAnnual EarningsimprovingCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 86%
LLeader vs LaggardlaggardRS: -8
IInstitutional SponsorshippassInst: 23%
MMarket DirectionneutralNeutral

Sector: Healthcare

Ranked #78 of 117 · Sector avg: 46

View all Healthcare signals →
Related Tickers
ATX 59PNV 56IMM 55EYE 55AHC 55
Compare:NEU vs ATXNEU vs PNVNEU vs IMM
Scout Pro — Deeper Analysis for NEU
Try Pro free for 30 days
Share this analysis

Track NEU and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and conviction scoring for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required